What do systematic reviews say?

Pyridoxal 5 phosphate (vitamin B6) vs placebo

Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Discontinuation of Vitamin B6 compared with placebo (low certainty).

• Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
  RR 8.72 [0.51, 149.75]
  2 studies · 65 participants
  Low

Pyridoxal 5 phosphate (vitamin B6) vs placebo

Pyridoxal 5 phosphate (vitamin B6) may leads to higher clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline… compared with placebo (low certainty).

• Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
  RR 19.97 [2.87, 139.19]
  2 studies · 65 participants
  Low

Pyridoxal 5 phosphate (vitamin B6) vs placebo

Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Other adverse effects than tardive dyskinesia Self‐report by… compared with placebo (low certainty).

• Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
  RR 3.97 [0.2, 78.59]
  2 studies · 65 participants
  Low

Pyridoxal 5 phosphate (vitamin B6) vs placebo

Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in tardive dyskinesia: Deterioration in tardive dyskinesia symptoms ESRS1 compared with placebo (low certainty).

• Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 3.14]
  2 studies · 65 participants
  Low

Pyridoxal 5 phosphate (vitamin B6) vs placebo

• Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Low

Pyridoxal 5 phosphate (vitamin B6) vs placebo

• Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Low